Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

M0696

Sigma-Aldrich

Anti-MNK2 (N-terminal) antibody produced in rabbit

enhanced validation

~1.0 mg/mL, affinity isolated antibody, buffered aqueous solution

Synonyme(s) :

Anti-GPRK7, Anti-MAP kinase interacting serine/threonine kinase 2, Anti-MKNK2

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.44

Source biologique

rabbit

Niveau de qualité

Conjugué

unconjugated

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

polyclonal

Forme

buffered aqueous solution

Poids mol.

antigen ~50 kDa

Espèces réactives

rat (predicted), human, mouse (predicted)

Validation améliorée

recombinant expression
Learn more about Antibody Enhanced Validation

Concentration

~1.0 mg/mL

Technique(s)

immunocytochemistry: 2-5 μg/mL using paraformadehyde fixed HEK-293T cells transfected with human MNK2
immunoprecipitation (IP): 2-4 μg using lysates of HEK-293T cells transfected with human MNK2
indirect immunofluorescence: suitable
western blot: 1-2 μg/mL using lysates of HEK-293T cells transfected with human MNK2

Numéro d'accès UniProt

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... MKNK2(2872)
mouse ... Mknk2(17347)
rat ... Mknk2(299618)

Description générale

MNK2 is a serine threonine kinase that phosphorylates endogenous eIF4E and thereby regulates protein translation and cell growth. This kinase inhibits apoptotic responses induced by arsenic trioxide. MNK2 has two distinct splice forms, namely; MNK2a and MNK2b. The localization and function of MNK2 splice variants are directed by their N and C termini . Anti-MNK2 (N-terminal) antibody is specific for human MNK2. The antibody is also expected to react with mouse and rat MNK2. In immunoblotting, staining of the MNK2 band is specifically inhibited by the immunizing peptide.

Immunogène

synthetic peptide corresponding to amino acids 51-64 of human MNK2 (corresponding to isoforms 1 and 2), conjugated to KLH via a C-terminal added cysteine residue. The corresponding sequence is conserved in human, rat, and mouse.

Application

Anti-MNK2 (N-terminal) antibody is suitable for use in immunocytochemistry (2-5 μg/mL using paraformaldehyde fixed, MNK2-transfected, HEK-293T cells) and indirect immunofluorescence. The antibody may also be used for immunoprecipitation (2-4 μg) and western blot (1-2 μg/mL) using lysates of HEK-293T cells transfected with human MNK2.

Forme physique

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Senthilmurugan Ramalingam et al.
Cancers, 11(3) (2019-03-06)
Currently, there are no effective therapies for patients with triple-negative breast cancer (TNBC), an aggressive and highly metastatic disease. Activation of eukaryotic initiation factor 4E (eIF4E) by mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) play a critical role
Y Shi et al.
Oncogene, 32(2), 190-197 (2012-03-01)
When mTOR inhibitor rapalogs prevent cap-dependent translation of cell-cycle proteins like c-myc, continuing tumor cell growth depends on cap-independent translation, which is mediated by internal ribosome entry sites (IRESes) located in the 5'-UTR (untranslated region) of transcripts. To investigate if
G C Scheper et al.
Molecular and cellular biology, 21(3), 743-754 (2001-01-12)
The cap-binding translation initiation factor eukaryotic initiation factor 4E (eIF4E) is phosphorylated in vivo at Ser209 in response to a variety of stimuli. In this paper, we show that the mitogen-activated protein kinase (MAPK) signal-integrating kinase Mnk2 phosphorylates eIF4E at
Blazej Dolniak et al.
The Journal of biological chemistry, 283(18), 12034-12042 (2008-02-27)
Arsenic trioxide (As(2)O(3)) is a potent inducer of apoptosis of malignant cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects are not well defined. We provide evidence that As(2)O(3) induces phosphorylation/activation of the
Gert C Scheper et al.
Molecular and cellular biology, 23(16), 5692-5705 (2003-08-05)
The cap-binding eukaryotic initiation factor eIF4E is phosphorylated by the mitogen-activated protein (MAP) kinase-interacting kinases (Mnk's). Three forms of the Mnk's exist in human cells: Mnk1, Mnk2a, and Mnk2b. These last two are derived from the same gene by alternative

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique